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A large percentage of patients with chronic heart failure 
(HF) have anemia, defined as hemoglobin (Hb) of <12 
g/dl, hovering around 30% in non-hospitalized HF patients 
and about 50% of hospitalized patients.1,2 The presence of 
anemia is an independent risk factor, associated with 
increased rates of mortality, HF hospitalization and 
morbidity. The cause of anemia in HF is multifactorial 
with 63.8% of patients having at least two factors that 
cause anemia. Chronic kidney insufficiency, iron 
deficiency, vitamin B12 deficiency, hemodilution, chronic 
diseases, and cachexia are the most common causes.3  
 
FIGURE 1. CAUSES OF ANEMIA IN HEART FAILURE 
 
Iron deficiency with or without anemia is common in 
patients with HF, relates to disease severity, and is a strong 
and independent predictor of outcome.4 Iron deficiency is 
defined as a ferritin level < 100μg/L or ferritin level 100-
299 μg/L with a transferrin saturation < 20%.4 Anemic 
patients were more often iron deficient than non anemic 
patients.  There are two types of iron deficiency, the 
absolute and the functional iron deficiency (Fig. 2).    
In absolute iron deficiency there is a reduction in 
transferrin saturation (%TSat) and in serum ferritin and 
this is associated with reduced total body iron stores often 
related to iron mechanisms and erythropoesis.5,6   
 
Commonest causes comprise low dietary iron, poor 
gastrointestinal (GI) absorption, impaired GI absorption 
and GI blood loss, drug interaction (e.g. omeprazole), 
reduced absorption of food and menorrhagia . In functional 
iron deficiency, %TSat is reduced but serum ferritin is 
normal or elevated and body stores are normal or elevated. 
This reflects insufficient iron supply to meet the 
requirement despite normal or abundant body iron stores, 
because iron is trapped inside the cells of the reticulo-
endothelial system and is not disposable for cellular 
metabolism.5,6 It is believed to be mainly caused by 
proinflammatory activation which causes hepsidin 
overproduction.7 One study conducted by Nanas et al. used 
the criterion of bone marrow iron staining to determine the 
prevalence of iron deficiency in patients with HF. They 
found that 73% of patients with advanced HF and anemia 
had depleted iron stores. 8  Iron plays a key role in oxygen 
uptake, transport, and storage, in the oxidative metabolism 
of the skeletal muscle and erythropoiesis. If we consider 
anemia of chronic HF as anemia of chronic disease, then 
there will be increased uptake and retention of iron in the 
cells of the reticuloendothelial system. This is achieved by 
the expression of divalent metal transporter 1 (DMT 1), 
which is up-regulated by cytokines. Divalent metal 
transporter 1 mediates iron transport into the intestinal 
mucosal cells and into the activated macrophages, but the 
export of iron from these cells is inhibited by down-
regulation of the expression of ferroportin by means of an 
increase in hepsidin. Hepsidin is a peptide synthesized by 
the liver in response to an increase in transferrin saturation, 
microbial infection, or inflammation. 14-16 This protein also 
inhibits iron absorption from the gut, and hepsidin levels 
seem to reflect iron load and response to erythropoietin 
(EPO) rather than inflammation and EPO resistance. Thus, 
this implies normal or increased ferritin with low serum 
iron, low transferrin, low transferrin saturation and thus 
poor availability of iron in the bone marrow. In a recent 
study of 546 patients, iron deficiency (absolute or 
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functional) was found in 37% of patients, but not anemia; 
it was related to an increased risk of death or heart 
transplantation, reinforcing its importance as an 
independent predictor of unfavorable outcome.  
Iron deficiency is an emerging problem in chronic HF, 
associated with disease severity; higher New York Heart 
Association (NYHA) functional class and higher NT-
proBNP level, lower mean corpuscular volume levels, 
decreased renal function, decreased exercise capacity 
(shorter distance covered during the 6-minute walking test, 
lower peak-oxygen consumption during cardiopulmonary 
exercise testing), and lower quality of life. 4 Iron deficiency 
causes dysfunction of myocardium and skeletal muscles 
because these organs have high energy demands, and their 
function is depending on intact iron metabolism. As 
already mentioned, iron deficiency is a strong and 
independent predictor of outcome and its correction is very 
important for improvement of cardiac function and 
functional capacity, to help prevent the progression of 
renal failure, markedly reduce hospitalization and diuretic 
doses, and improve self-assessed quality of life. 9 
Therefore, it is important to study the iron metabolism of 
patients with chronic HF, whether iron deficiency is 
absolute or functional, and start treatment with intravenous 
(IV) iron. On the other hand, one might think that oral iron 
could possibly achieve similar results but the answer for 
the oral use is most likely negative for a variety of reasons. 
Absorption of oral iron preparations in the anemia of 
chronic disease is blocked by hepsidin,12 these 
preparations are not well tolerated, mostly due to GI side 
effects, and drug interactions may occur, such as with 
proton pump inhibitors.13  
The effect of iron on the heart may by related not only 
to improved oxygenation owing to increased Hb, but also 
directly to its effects on the mitochondrial and other 
cellular elements that require iron, and not necessarily 
related to the correction of the anemia per se. 10 Seven 
studies refer to the result of effect of IV iron 
supplementation in patients with chronic HF. Two of these 
include both anemic and non-anemic patients. The first 
study by Bolger et al. including 16 patients with stable HF, 
NYHA class II-III, left ventricular ejection fraction 
(LVEF) of 26+13%, showed that IV iron therapy without 
co-administration of EPO was simple and safe, improved 
exercise capacity, decreased symptoms and increased Hb 
in anemic patients with chronic HF.18  In the double-blind, 
randomized, placebo-controlled study by Toblli et al. it 
was shown that therapy with IV iron and without EPO in 
patients with chronic HF and moderate chronic renal 
failure, reduced plasma NT-proBNP  and inflammatory 
markers and produced improvement in LVEF, NYHA 
class, exercise tolerance and renal function.19 The Ferric 
Iron Sucrose in Heart Failure (FERRIC-HF) study showed 
that 16 weeks of IV iron therapy in anemic and non anemic 
HF patients with iron deficiency, improved exercise 
tolerance and symptoms and the benefits were more 
evident in non anemic patients with iron deficiency.10 In 
one study by Drakos et al. the administration of IV iron 
with erythropoietin in HF patients with anemia and iron 
deficiency, measured by bone marrow aspiration, 
increased Hb about the same as did erythropoietin alone.20 
In the study of Usmanov et al. it was demonstrated that in 
patients with optimally-treated chronic HF, NYHA class 
III-IV, Hb<11g/dL and chronic kidney insufficiency, 
treatment with IV with iron for 26 weeks, produced a 
significant increase in Hb in anemic patients and in a large 
proportion improved cardiac remodeling, assessed by 
echocardiography, and NYHA class but not in those 
patients with NYHA class IV.21 Comin-Colet et al. 
reported that long-term combined therapy with IV iron and 
EPO in elderly patients with advanced HF, mild-to-
moderate renal dysfunction, and anemia, corrected Hb and 
creatinine levels, improved symptoms, reduced  plasma 
NT-pro-BNP and cardiovascular hospitalizations.22 The 
FAIR-HF study was a randomized double-blind placebo-
controlled multicenter trial, which included the greatest 
number of patients. Randomized patients with reduced left 
ventricular ejection fraction, with or without anemia and 
iron deficiency, to intravenous ferric carboxymaltose, and 
demonstrated that iron IV in those patients with HF 
improves their functional status after 4 weeks and 
increases Hb, and that is independent of anemic status.11   
In conclusion, iron is an important biometal and its 
deficiency is seen in many chronic diseases such as CHF. 
Correction of iron deficiency is important for those 
patients with or without anemia and CHF because it 
improves the symptoms and quality of life, and that justify 
more research. 
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Table 1. Studies of Intravenous Iron Supplementation in Patients With Heart Failure 
 
References Study Design/ 
No of pts 
Period Criteria/Features Treatment Main Results 
Bolger et al, 2006 Uncontrolled/ 
16 pts 
92+6 d Hb<12 g/dl, mean age 68, NYHA 
class II-III, mean EF 26% 
1 g IV iron 
sucrose x 12 d 
↑Hb/Ferritin/TSat/MLHFQ/6MWD 
↓Sx 
Tobli et al, 2007 Double-blind, 
randomized / 40 
pts 
6 
months 
Hb<12.5 g/dl, TSat<20%, 
Ferritin<100 ng/ml, CrCl<ml/min, 
EF<35%, NYHA class II-IV 
IV iron sucrose 
200 mg / week x 5 
weeks 
↑Hb/TSat/Ferritin/CrCl/ MLHFQ 
/6MWD 
↓NYHA class/NT-ProBNP 
Okonko DO, 2008 FERRIC-HF: 
randomized/ 35 
pts 
16 
weeks 
Mean age 64, MVO2 14, Hb 12.5, 
Ferritin<100 ng/ml or ferritin 100-
300 & TSat<20% 
IV iron sucrose ↑Hb/TSat/Ferritin/MVO2 
↓NYHA class 
Usmarov 2008 Uncontrolled / 
32 pts 
26 
weeks 
H<11 g/dl, NYHA class II-IVb IV iron ↑Hb 
↓remodeling/NYHA class 
Drakos et al, 2009 Randomized / 
16 pts 
3 
months 
Iron-deficiency anemia 2 groups: IV iron / 
IV iron+EPO 
↑Hb 
Comi-Colet, 2009 Uncontrolled / 
65 pts 
15 
months 
Mean age 74, EF 34.5%, Hb 10.9, 
Cr 1.5, NT-proBNP 4256, NYHA 
III-IV 
IV iron+EPO ↑Hb 
↓NT-proBNP/NYHA class / 
mortality/ hospitalization 
Anker et al, 2009 FAIR-HF, 
randomized / 
459 pts 
24 
weeks 
EF<40%, NYHA II, EF<45%, 
NYHA III, Hb 9.5-13.5g/dl, ferritin 
<100 μg/L or 100-299 μg/L 
IV iron vs placebo ↑Hb/ferritin/%TSat/ MCV/ 
↓PGA / NYHA class  
 
CrCl = creatinine clearance; EF = (left ventricular) ejection fraction; EPO = erythropoietin; FAIR-HF = Ferinject Assessment in patients 
with Iron deficiency and CHF; FERRIC-HF = Ferric iron sucrose in Heart Failure; Hb = hemoglobin; IV = intravenous; MCV = mean 
corpuscular volume; MLHFG = Minnesota Living with Heart Failure score; NT-proBNP = N-terminal pro-B-type natriuretic peptide; 
NYHA = New York Heart Association; PGA = patient global assessment; pts = patients; p VO2 = peak oxygen consumption; TSat = 
transferrin saturation; 6MWD = 6 minute walking distance;  
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